Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
Metabolic diseases are risk factors for severe Coronavirus disease (COVID-19), which have a close relationship with metabolic dysfunction-associated fatty liver disease (MAFLD). To evaluate the presence of MAFLD and fibrosis in patients with COVID-19 and its association with prognosis. Retrospective...
Uložené v:
| Vydané v: | Digestive and liver disease Ročník 53; číslo 5; s. 525 - 533 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Netherlands
Elsevier Ltd
01.05.2021
Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd |
| Predmet: | |
| ISSN: | 1590-8658, 1878-3562, 1878-3562 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
Buďte prvý, kto okomentuje tento záznam!